Epithelial separator demonstrates excellent performance
July 15th 2005Washington, DC—The automated, disposable Epi-K epithelial separator (Moria) safely and reliably cleaves the epithelium to create high-quality flaps and beds, and its use in Epi-LASIK is associated with favorable results with regard to postoperative pain and visual recovery profiles, said Daniela Jardim, MD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Customized ablation treatments produce excellent results
July 15th 2005Washington, DC—The CustomCornea (Alcon Laboratories Inc.) or CustomVue (VISX) platforms seem to offer excellent outcomes in wavefront-guided LASIK for myopia. However, induced aberration appears to be less with CustomCornea treatment, especially after nomogram adjustment for the CustomVue procedure, and that difference is apparent clinically in terms of contrast sensitivity results, according to Stephen G. Slade, MD.
Evolving techniques enhance results with keratoprosthesis
July 15th 2005Washington, DC—Accruing experience with the AlphaCor (Argus Biomedical) synthetic keratoprosthesis has led to the identification of risk factors for complications along with the development of protective procedures that are enabling better outcomes, said R. Doyle Stulting, MD, PhD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Wavefront-optimized LASIK comparable to wavefront-guided
July 15th 2005Washington, DC—The initial results of a study of the MEL-80 excimer laser (Carl Zeiss Meditec) indicate that the laser has an excellent safety and efficacy profile when performing LASIK for myopia. The patients recovered their visual function rapidly, and the uncorrected visual acuity (UCVA) levels in this trial in which wavefront-guided ablation was not performed were comparable to studies in which wavefront-guided ablation was performed using other lasers.
Additional mechanism of action possible in accommodative lens
July 15th 2005Washington, DC—The crystalens (eyeonics), an accommodating IOL approved for use in cataract patients, provides distance, intermediate, and near vision 3 years after implantation that are slightly better than the 1-year results. Optical tilt or optic flexure with induced astigmatism in conjunction with the traditional mechanism of action is hypothesized to play a role in the near visual acuity, according to Steven J. Dell, MD, speaking at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting.
Finding the best technique for wavefront-guided LASIK
July 15th 2005Washington, DC—Early outcomes after wavefront-guided LASIK may be better when using the femtosecond laser microkeratome (IntraLase Corp.) for flap creation compared with mechanical microkeratomes, but show no difference whether the procedure is performed in a single session or with a staged approach regardless of the microkeratome used.
Novel IOL changes shape to achieve accommodation
July 15th 2005Washington, DC—A novel IOL in development from PowerVision may represent the most promising concept yet for an accommodative implant, said Louis D. "Skip" Nichamin, MD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Evolution in CK technique revolutionizes outcomes
July 15th 2005Washington, DC—Use of the neutral-pressure "Light Touch" technique for conductive keratoplasty (CK, Refractec) improves predictability, minimizes induced astigmatism, affords faster visual recovery, and provides the opportunity for higher corrections compared with the original approach.
Fibrin tissue adhesive has benefits in pterygium surgery
July 15th 2005Washington, DC—Fibrin tissue adhesive (Tisseel VH Fibrin Sealant, Baxter BioSurgery) is a viable and attractive alternative to suturing in pterygium surgery with conjunctival-limbal autograft, said John A. Hovanesian, MD, at the World Cornea Congress V.
Topical chemotherapy an alternative for PAM with atypia
July 15th 2005Washington, DC—Topical mitomycin-C (MMC) (Mutamycin, Bristol-Myers Oncology) is an effective treatment for conjunctival primary acquired melanosis (PAM) with atypia, and may even be considered a superior alternative to surgical excision and cryotherapy, said Joseph Frucht-Pery, MD, at World Cornea Congress V.
Advanced AMD places patient at increased risk of mortality
July 15th 2005Madison, WI—An association between mortality and age-related macular degeneration (AMD) was found in the Age-Related Eye Disease Study (AREDS). All-cause mortality increased with increasing severity of disease, with category 4 AMD having a significantly increased association with death compared with category 1 AMD. A protective effect was seen for zinc in participants randomly assigned to therapy with the mineral.
Corneal disease remains major cause of blindness
July 15th 2005Washington, DC—Corneal pathology continues to be a major cause of blindness in developing countries of the world, and nearly all of the diseases and conditions leading to corneal blindness are preventable or treatable with existing knowledge and technology, said Gullapalli N. Rao, MD, at World Cornea Congress V.
Age-related maculopathy: a product of genetics and environment?
July 15th 2005Fort Lauderdale, FL—The phenotype of age-related macular disease provides information about the genes that confer risk or the environmental factors that are involved in risk in a particular individual, according to Alan Bird, MD, who spoke at the annual meeting of the Association for Research in Vision and Ophthalmology.
AAO supports bill to fund children's vision care
July 1st 2005Washington, DC—The American Academy of Ophthalmology (AAO) is joining other professional organizations to support the "Children's Access to Vision Care Act of 2005," a bill that would provide $75 million in state grants for eye exams and other treatment for uninsured children who fail vision screenings.
Botulinum toxin provides many cosmetic, functional uses
July 1st 2005Cleveland—Comprehensive ophthalmologists who understand the mechanism of botulinum toxin type A (Botox, Allergan) and the underlying anatomy can find many functional and cosmetic uses for botulinum toxin in their practices, said Julian D. Perry, MD.
IOL insertion system offers single-handed planar delivery
July 1st 2005Washington, DC—The SofPort Easy-Load Lens Delivery System (Bausch & Lomb) seems to be a giant step forward in IOL delivery. The system allows surgeons to load the lens into the inserter without the use of forceps, which eliminates damage to the IOL. The system is easy to use and cuts down surgical time, explained P. Dee G. Stephenson, MD, during the annual meeting of the American Society of Cata-ract and Refractive Surgery.
Apodized diffractive IOL gives high visual satisfaction
July 1st 2005Washington, DC—Cataract surgery patients who received the AcrySof apodized diffractive IOL (ReSTOR, Alcon Laboratories) experienced a significantly higher degree of satisfaction with their vision compared with recipients of an acrylic foldable monofocal IOL, reported Robert J. Cionni, MD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Scotopic vision may be affected by blue-blocking lens
July 1st 2005Washington, DC—An IOL that blocks blue light leads to impairment of scotopic vision at the short wavelengths important for rod-mediated vision. The significance of this impairment in terms of the patient's visual performance remains to be determined, explained Gregory Jackson, PhD, at the American Society of Cataract and Refractive Surgery annual meeting.
Blue light-filtering IOL does not hinder night driving
July 1st 2005Washington, DC—The improvements in health-related quality of life (HRQOL) made with the AcrySof Natural IOL (Alcon Laboratories), an IOL that attenuates blue light, were not statistically different from the results achieved with the AcrySof single-piece conventional IOL (Alcon). The Natural IOL did not adversely affect night driving or other common lifestyle events that are measured by a HRQOL questionnaire, reported Paul Ernest, MD, at the American Society of Cataract and Refractive Surgery annual meeting.
Square-edge design of lens effective against PCO
July 1st 2005Washington, DC—The three-piece square-edge design of the Tecnis IOL platform (AMO) seems to protect the eye against development of posterior capsular opacification (PCO) by preventing migration of epithelial cells for at least 3 years after implantation, reported Michael Colvard, MD, FACS, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Bimanual microincision surgery advantageous for RLE
July 1st 2005Washington, DC—Accumulating experience demonstrates the efficacy and safety of refractive lens exchange (RLE) performed with bimanual microincision phaco, said I. Howard Fine, MD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Novel NSAID prodrug safe, effective in cataract surgery
July 1st 2005Washington, DC—Results of a clinical trial demonstrate the efficacy and safety of the investigational nonsteroidal anti-inflammatory drug (NSAID) nepafenac 0.1% ophthalmic suspension (Alcon Laboratories) for reducing anterior segment inflammation and minimizing pain after cataract surgery, said Stephen S. Lane, MD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Coaxial microincision surgery possible with phaco sleeve
July 1st 2005Washington, DC—The combination of a new "ultra-sleeve" (Alcon Laboratories) with the Infiniti flare tip (Alcon) allows coaxial phacoemulsification to be performed with high efficiency through a 2.1-mm incision, said Richard J. Mackool, MD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Preoperative topical NSAID yields improved phaco efficiency
July 1st 2005Washington, DC—The introduction of a topical nonsteroidal anti-inflammatory drug (NSAID) 3 days before phacoemulsification produced excellent results in terms of surgical efficacy and outcomes, according to Eric D. Donnenfeld, MD, at the American Society of Cataract and Refractive Surgery annual meeting.